Idarubicin and High Dose Cytarabine: A New Salvage Treatment for Refractory or Relapsing Non-Hodgkin's Lymphoma |
| |
Authors: | Patrick Dufour Ricardo Mors Patrice Berthaud Thierry Lamy Jean-Pierre Bergerat Raoul Herbrecht Frederic Maloisel Bruno Audhuy Bruno Lioure Cathy Giron Patrick Hurteloup Francis Oberling |
| |
Affiliation: | a Departement Onco-Hematologie, Hopitaux Universitaires de Strasbourg, Strasbourg Cedexb Service Onco-Hematologie, Hopital Louis Pasteur, Colmar Cedexc Farmitalia Carlo Erba, Rueil Malmaison Cedexd Service Hematologie, CHU de Rennes, Rennes, France |
| |
Abstract: | Twenty three patients with relapsing (n = 11) or refractory (n = 12) non-Hodgkin's lymphoma (NHL) to one or two prior anthracycline based combination chemotherapy regimens were treated as second or third line regimen with 3 induction cycles of Idarubicin (IDA) (7 mg/m2/d IV dl-d3) and high dose cytarabine (HD Ara-C) (1 g/m2/12 h IV dl-d3), each cycle was repeated every 3 weeks. Responding patients received a maintenance therapy with monthly cycles of IDA : 15 mg/m2 dl-d3, Etoposide 100 mg/m2 dl-d3, both by oral route. Twenty two patients are evaluable and we observed 13 CR and 1 PR with an overall response rate of 61 % (14/23; 95% Cl = 38.5% 80.3%). The median time to progression was 32 months (6.5 - 63 + m.). The response rate to IDA-HD Ara C was not different for patients with (n = 14) or without (n = 9) objective response to the last prior therapy. The main toxicity was hematological: all patients experienced grade 4 neutropenia and 22 patients had grade 4 thrombopenia, but there were no toxic deaths. IDA and HD-Ara-C combination is highly effective in refractory or relapsed NHL. As hematological toxicity was the limiting factor for further escalation of dose-intensity, further studies might include hematopoietic growth factors support in the therapeutic scheme. |
| |
Keywords: | lymphoma non-Hodgkin's—salvage therapy—idarubicin—cytarabine |
本文献已被 InformaWorld 等数据库收录! |
|